MA56288A1 - Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique - Google Patents

Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique

Info

Publication number
MA56288A1
MA56288A1 MA56288A MA56288A MA56288A1 MA 56288 A1 MA56288 A1 MA 56288A1 MA 56288 A MA56288 A MA 56288A MA 56288 A MA56288 A MA 56288A MA 56288 A1 MA56288 A1 MA 56288A1
Authority
MA
Morocco
Prior art keywords
solid state
potassium channel
channel modulator
crystal forms
state crystal
Prior art date
Application number
MA56288A
Other languages
English (en)
Inventor
Paul Robert Bichler
Gregory N Beatch
Jean-Jacques A Cadieux
Matthew David Tandy
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA56288A1 publication Critical patent/MA56288A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Liquid Crystal Substances (AREA)
  • Transmitters (AREA)

Abstract

La présente invention concerne des formes à l'état solide d'un modulateur sélectif du canal potassique et des compositions pharmaceutiques comprenant les formes cristallines à l'état solide, ainsi que des excipients pharmaceutiquement acceptables, et des procédés de préparation et d'utilisation des formes à l'état solide et des compositions pharmaceutiques de celles-ci.
MA56288A 2019-10-10 2020-10-09 Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique MA56288A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913574P 2019-10-10 2019-10-10
PCT/US2020/055129 WO2021072307A1 (fr) 2019-10-10 2020-10-09 Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique

Publications (1)

Publication Number Publication Date
MA56288A1 true MA56288A1 (fr) 2023-01-31

Family

ID=73040296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56288A MA56288A1 (fr) 2019-10-10 2020-10-09 Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique

Country Status (17)

Country Link
US (3) US11091441B2 (fr)
EP (1) EP4041713A1 (fr)
JP (1) JP2022552187A (fr)
KR (1) KR20220080119A (fr)
CN (1) CN115190874A (fr)
AU (1) AU2020364142A1 (fr)
BR (1) BR112022006583A2 (fr)
CA (1) CA3153752A1 (fr)
CL (1) CL2022000881A1 (fr)
CO (1) CO2022005890A2 (fr)
CR (1) CR20220187A (fr)
IL (1) IL292005A (fr)
MA (1) MA56288A1 (fr)
MX (1) MX2022004209A (fr)
PE (1) PE20221023A1 (fr)
TW (1) TW202128627A (fr)
WO (1) WO2021072307A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3207191A1 (fr) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Ouvreur de canaux potassiques sensibles a la tension destine a etre utilise dans le traitement de l'anhedonie
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
ES2420960T3 (es) * 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
HRP20231447T1 (hr) 2018-05-11 2024-03-01 Xenon Pharmaceuticals Inc. Postupci za povećanje bioraspoloživosti i izloženosti naponski upravljanog otvarača kalijevih kanala

Also Published As

Publication number Publication date
CR20220187A (es) 2022-07-21
CL2022000881A1 (es) 2023-01-13
EP4041713A1 (fr) 2022-08-17
WO2021072307A1 (fr) 2021-04-15
AU2020364142A1 (en) 2022-04-21
JP2022552187A (ja) 2022-12-15
US20210147363A1 (en) 2021-05-20
CO2022005890A2 (es) 2022-05-31
TW202128627A (zh) 2021-08-01
PE20221023A1 (es) 2022-06-16
US20240279182A1 (en) 2024-08-22
MX2022004209A (es) 2022-05-03
US20220064120A1 (en) 2022-03-03
BR112022006583A2 (pt) 2022-06-28
CA3153752A1 (fr) 2021-04-15
KR20220080119A (ko) 2022-06-14
IL292005A (en) 2022-06-01
CN115190874A (zh) 2022-10-14
US11091441B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
MA56288A1 (fr) Formes cristallines à l'état solide d'un modulateur sélectif du canal potassique
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA49235B1 (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MX2023000835A (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este.
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA29627B1 (fr) Modifications cristallines de la pyraclostrobine
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
NO20081816L (no) Farmasoytiske sammensetninger inneholdende pregabalin
TR199802698T2 (xx) Valsartan�n kat� oral doz formlar�.
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NZ771961A (en) Rapidly disintegrating oral film matrix
CY1108453T1 (el) Διαδικασια για την παρασκευη επλερενονης
MA33561B1 (fr) Dérivés d'isoxazolidine
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina
EA202190246A1 (ru) Производные тиадиазина
MX2021010338A (es) Composicion farmaceutica que contiene acetominofeno e ibuprofeno.
DK1690549T3 (da) Immunoterapeutisk middel, som anvendes til den kombinerede behandling af tuberkulose sammen med andre lægemidler